19F NMR Studies of Plasminogen Activator Inhibitor-1

Biochemistry

Volumn 43, Issue 6, 2004, Pages 1507-1519

  Abbott, Glenn L ^a,e   Blouse, Grant E ^b,c   Perron, Michel J ^b,c   Shore, Joseph D ^b,c   Luck, Linda A ^d   Szabo, Arthur G ^e  

^a UNIVERSITY OF WATERLOO   (Canada)

^b HENRY FORD HEALTH SCIENCES CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CLARKSON UNIVERSITY   (United States)

^e WILFRID LAURIER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSYNTHESIS; ENZYME INHIBITION; ENZYMES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORGANIC ACIDS; RATE CONSTANTS; STOICHIOMETRY;

MUTANTS; STRUCTURAL CHANGES;

BIOCHEMISTRY;

PHENYLALANINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TRYPTOPHAN; 5 FLUOROTRYPTOPHAN; 5-FLUOROTRYPTOPHAN; DRUG DERIVATIVE; FLUORINE; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACID SEQUENCE; ARTICLE; BIOSYNTHESIS; COMPLEX FORMATION; COVALENT BOND; FIBRINOLYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; STOICHIOMETRY; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; HYDROLYSIS; NUCLEAR MAGNETIC RESONANCE; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

FLUORINE; HUMANS; HYDROLYSIS; MUTAGENESIS, SITE-DIRECTED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE PLASMINOGEN ACTIVATOR; TRYPTOPHAN;

EID: 1042288297     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi035618a     Document Type: Article

References (78)

1. Potempa, J., Korzus, E., and Travis, J. (1994) The Serpin Superfamily of Proteinase Inhibitors: Structure, Function, and Regulation, J. Biol. Chem. 269, 15957-15960.
2. Gils, A., and Declerck, P. J. (1998) Structure-Function Relationships in Serpins: Current Concepts and Controversies, Thromb. Haemostasis 80, 531-541.
3. Irving, J. A., Pike, R. N., Lesk, A. M., and Whisstock, J. C. (2000) Phylogeny of the Serpin Superfamily: Implications of Patterns of Amino Acid Conservation for Structure and Function, Genome Res. 10, 1845-1864.
4. Silverman, G. A., Bird, P. I., Carrell, R. W., Church, F. C., Coughlin, P. B., Gettins, P. G. W., Irving, J. A., Lomas, D. A., Luke, C. J., Moyer, R. W., Pemberton, P. A., Remold-O'Donnell, E., Salvesan, G. S., Travis, J., and Whisstock, J. C. (2001) The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins, J. Biol. Chem. 276, 33293-33296.
5. Gettins, P. G. W. (2002) Serpin Structure, Mechanism, and Function, Chem. Rev. 102, 4751-4803.
6. Schick, C., Pemberton, P. A., Shi, G. P., Kamachi, Y., Cataltepe, S., Bartuski, A. J., Gornstein, E. R., Bromme, D., Chapman, H. A., and Silverman, G. A. (1998) Cross-Class Inhibition of the Cysteine Proteinases Cathepsins K, L, and S by the Serpin Squamous Cell Carcinoma Antigen 1: A Kinetic Analysis, Biochemistry 37, 5258-5266.
7. Irving, J. A., Steenbakkers, P. J., Lesk, A. M., Op den Camp, H. J., Pike, R. N., and Whisstock, J. C. (2002) Serpins in Prokaryotes, Mol. Biol. Evol. 19, 1881-1890.
8. 1-Antitrypsin for Structure and Function of Serpins, Biochemistry 28, 8951-8966.
9. Schechter, I., and Berger, A. (1967) On the size of the active site in proteases. I. Papain, Biochem. Biophys. Res. Commun. 27, 157-162.
10. Loebermann, H., Tokuoka, R., Deisenhofer, J., and Huber, R. (1984) Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function, J. Mol. Biol. 177, 531-557.
11. 1-Antitrypsin, J. Mol. Biol. 295, 651-665.
12. Lawrence, D. A., Ginsburg, D., Day, D. E., Berkenpas, M. B., Verhamme, I. M., Kvassman, J.-O., and Shore, J. D. (1995) Serpin-Protease Complexes Are Trapped as Stable Acyl-Enzyme Intermediates, J. Biol. Chem. 270, 25309-25312.
13. Huntington, J. A., Read, R. J., and Carrell, R. W. (2000) Structure of a serpin-protease complex shows inhibition by deformation, Nature 407, 923-926.
14. Engh, R. A., Huber, R., Bode, W., and Schulze, A. J. (1995) Divining the serpin inhibition mechanism: a suicide substrate 'springe', Trends Biotechnol. 13, 503-510.
15. Lawrence, D. A., Olson, S. T., Palaniappan, S., and Ginsburg, D. (1994) Serpin Reactive Center Loop Mobility Is Required for Inhibitor Function but Not for Enzyme Recognition, J. Biol. Chem. 269, 27657-27662.
16. Stratikos, E., and Gettins, P. G. W. (1997) Major proteinase movement upon stable serpin-proteinase complex formation, Proc. Natl. Acad. Sci. U.S.A. 94, 453-458.
17. Plotnick, M. I., Mayne, L., Schechter, N. M., and Rubin, H. (1996) Distortion of the Active Site of Chymotrypsin Complexed with a Serpin, Biochemistry 35, 7586-7590.
18. 1-Proteinase Inhibitor Pittsburgh, J. Biol. Chem. 273, 15582-15589.
19. Stratikos, E., and Gettins, P. G. W. (1999) Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A, Proc. Natl. Acad. Sci. U.S.A. 96, 4808-4813.
20. 1-Proteinase Inhibitor Pittsburgh-Trypsin Covalent Complex, Biochemistry 40, 6284-6292.
21. Ginsburg, D., Zehab, R., Yang, A. Y., Rafferty, U. M., Andreasen, P. A., Nielsen, L., Dano, K., Lebo, R. V., and Gelehrter, T. D. (1986) cDNA Cloning of Human Plasminogen Activator-Inhibitor from Endothelial Cells, J. Clin. Invest. 78, 1673-1680.
22. van Mourik, J. A., Lawrence, D. A., and Loskutoff, D. J. (1984) Purification of an Inhibitor of Plasminogen Activator (Antiactivator) Synthesized by Endothelial Cells, J. Biol. Chem. 259, 14914-14921.
23. Kruithof, E. K. O., Tran-Thang, C., Ransijn, F., and Bachmann, F. (1984) Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma, Blood 64, 907-913.
24. Blouse, G. E., Perron, M. J., Thompson, J. H., Day, D. E., Link, C. A., and Shore, J. D. (2002) A Concerted Structural Transition in the Plasminogen Activator-1 Mechanism of Inhibition, Biochemistry 41, 11997-12009.
25. Mottonen, J., Strand, A., Symersky, J., Sweet, R. M., Danley, D. E., Geoghegan, K. F., Gerard, R. D., and Goldsmith, E. J. (1992) Structural basis for latency in plasminogen activator inhibitor-1, Nature 355, 270-273.
26. Sharp, A. M., Stein, P. E., Pannu, N. S., Carrell, R. W., Berkenpas, M. B., Ginsburg, D., Lawrence, D. A., and Read, R. J. (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion, Struct. Fold. Des. 7, 111-118.
27. Nar, H., Bauer, M., Stassen, J.-M., Lang, D., Gils, A., and Declerck, P. J. (2000) Plasminogen Activator Inhibitor 1. Structure of the Native Serpin, Comparison to its Other Conformers and Implications for Serpin Inactivation, J. Mol. Biol. 297, 683-695.
28. Aertgeerts, K., DeBondt, H. L., De Ranter, C. J., and Declerck, P. J. (1995) Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1, Nat. Struct. Biol. 2, 891-897.
29. Boström, S., Deinum, J., Löfroth, J.-E., Wirth, M., and Kubista, M. (1990) Conformational Differences between Latent and Active Plasminogen Activator Inhibitor, PAI-1: A Spectroscopic Study, Thromb. Res. 59, 851-858.
30. Dwivedi, A. M., Woodeshick, R. W., Walton, H. L., and Reilly, T. M. (1991) A Spectroscopic Study of the Conformations of Active and Latent Forms of Recombinant Plasminogen Activator Inhibitor-1, Biochem. Biophys. Res. Commun. 175, 437-443.
31. Seetharam, R., Dwivedi, A. M., Duke, J. L., Hayman, A. C., Walton, H. L., Huckins, N. R., Kamerkar, S. M., Corman, J. I., Woodeshick, R. W., Wilk, R. R., and Reilly, T. M. (1992) Purification and Characterization of Active and Latent Forms of Recombinant Plasminogen Activator Inhibitor 1 Produced in Escherichia coli, Biochemistry 31, 9877-9882.
32. Lawrence, D. A., Olson, S. T., Palaniappan, S., and Ginsburg, D. (1994) Engineering Plasminogen Activator Inhibitor 1 Mutants with Increased Functional Stability, Biochemistry 33, 3643-3648.
33. Sancho, E., Declerck, P. J., Price, N. C., Kelly, S. M., and Booth, N. A. (1995) Conformational Studies on Plasminogen Activator Inhibitor (PAI-1) in Active, Latent, Substrate, and Cleaved Forms, Biochemistry 34, 1064-1069.
34. Schulze, A. J., Quarzago, D., and Andreasen, P. A. (1996) A spectroscopic study of the structures of latent, active and reactive-center-cleaved type-1 plasminogen-activator inhibitor, Eur. J. Biochem. 240, 550-555.
35. 19F NMR to Probe Protein Structure and Conformational Changes, Annu. Rev. Biophys. Biomol. Struct. 25, 163-195.
36. Gerig, J. T (1994) Fluorine NMR of Proteins, Prog. Nucl. Magn. Reson. Spectrosc. 26, 293-370.
37. Wüthrich, K. (1986) NMR of Proteins and Nucleic Acids, Wiley, New York.
38. 1H NMR Spectroscopy, Biochemistry 26, 1391-1398.
39. Gettins, P., and Harten, B. (1988) Properties of Thrombin- and Elastase-Modified Human Antithrombin III, Biochemistry 27, 3634-3639.
40. 1-Proteinase Inhibitor, Biochemistry 30, 9054-9060.
41. Matheson, N. R., van Halbeek, H., and Travis, J. (1991) Evidence for a Tetrahedral Intermediate Complex during Serpin-Proteinase Interactions, J. Biol. Chem. 266, 13489-13491.
42. 1H NMR Spectroscopic Studies on the Interactions between Human Plasma Antithrombin III and Defined Low Molecular Weight Heparin Fragments, Biochemistry 31, 2286-2294.
43. 1H nuclear magnetic resonance and Fourier transform infrared spectroscopy, J. Mol. Biol. 228, 1235-1254.
44. 15N HSQC NMR as a Sensitive Nonperturbing Monitor of Conformation, Biochemistry 39, 11884-11892.
45. Pervushin, K., Riek, R., Wider, G., and Wüthrich, K. (1997) Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution, Proc. Natl. Acad. Sci. U.S.A. 94, 12366-12371.
46. Salzmann, M., Pervushin, K., Wider, G., Senn, H., and Wüthrich, K. (1998) TROSY in triple-resonance experiments: new perspectives for sequential NMR assignment of large proteins, Proc. Natl. Acad. Sci. U.S.A. 95, 13585-13590.
47. Hogue, C. W. V., Rasquinha, I., Szabo, A. G., and McManus, J. P. (1992) A new intrinsic fluorescent probe for proteins. Biosynthetic incorporation of 5-hydroxytryptophan into oncomodulin, FEBS Lett. 310, 269-272.
48. Ross, J. B. A., Szabo, A. G., and Hogue, C. W. V. (1997) Enhancement of Protein Spectra with Tryptophan Analogues: Fluorescence Spectroscopy of Protein-Protein and Protein-Nucleic Acid interactions, Methods Enzymol. 278, 151-190.
49. Gettins, P., Choay, J., Crews, B. C., and Zettlmeiss, G. (1992) Role of Tryptophan 49 in the Heparin Cofactor Activity of Human Antithrombin III, J. Biol. Chem. 267, 21946-21953.
50. 19F NMR Studies of the D-Galactose Chemosensory Receptor. 1. Sugar Binding Yields a Global Structural Change, Biochemistry 30, 4248-4256.
51. 19F NMR study of the leucine-specific binding protein of Escherichia coli: mutagenesis and assignment of the 5-fluorotryptophan-labeled residues, Protein Eng. 15, 855-859.
52. Kunkel, T. A., Roberts, J. D., and Zakour, R. A. (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection, Methods Enzymol. 154, 367-382.
53. Kunkel, T. A., Bebenek, K., and McClary, J. (1991) Efficient site-directed mutagenesis using uracil-containing DNA, Methods Enzymol. 204, 125-139.
54. Blouse, G. E., Perron, M. J., Kvassman, J.-O., Yunus, S., Thompson, J. H., Betts, R. L., Lutter, L. C., and Shore, J. D. (2003) Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of Plasminogen Activator Inhibitor-1, Biochemistry 42, 12260-12272.
55. Olson, S. T., Bock, P. E., Kvassman, J.-O., Shore, J. D., Lawrence, D. A., Ginsburg, D., and Bjork, I. (1995) Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes, J. Biol. Chem. 270, 30007-30017.
56. Sambrook, J. E., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
57. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding assays, Anal. Biochem. 72, 248-254.
58. Kvassman, J.-O., and Shore, J. D. (1995) Purification of Human Plasminogen Activator Inhibitor (PAI-1) from Escherichia coli and Separation of its Active and Latent Forms by Hydrophobic Interaction Chromatography, Fibrinolysis 9, 215-221.
59. Vaughan, D. E., Declerck, P. J., Reilly, T. M., Park, K., Collen, D., and Fasman, G. D. (1993) Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1, Biochim. Biophys. Acta 1202, 221-229.
60. Wu, K., Urano, T., Ihara, H., Takada, Y., Fujie, M., Shikimori, M., Hashimoto, K., and Takada, A. (1995) The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis, Blood 86, 1056-1061.
61. Kvassman, J.-O., Verhamme, I., and Shore, J. D. (1998) Inhibitory Mechanism of Serpins: Loop Insertion Forces Acylation of Plasminogen Activator by Plasminogen Activator Inhibitor-1, Biochemistry 37, 15491-15502.
62. Abbott, G. L. (2003) Quantitation of Tryptophan Analogues Biosynthetically Incorporated into Proteins and Structural Investigation of Single Tryptophan Mutants of Plasminogen Activator Inhibitor-1, M. Sc. Thesis, University of Waterloo, Waterloo, ON, Canada.
63. Penke, B., Ferenczi, R., and Kovacs, K. (1974) A New Acid Hydrolysis Method for Determining Tryptophan in Peptides and Proteins, Anal. Biochem. 60, 45-60.
64. Delhaye, S., and Landry, J. (1986) High Performance Liquid Chromatography and Ultraviolet Spectrophotometry for Quantitation of Tryptophan in Barytic Hydrolysates, Anal. Biochem. 159, 175-178.
65. Tian, W. X., and Tsou, C. L. (1982) Determination of the rate constant of enzyme modification by measuring the substrate reaction in the presence of the modifier, Biochemistry 21, 1028-1032.
66. Waxman, E., Rusinova, E., Hasselbacher, C. A., Schwartz, G. P., Laws, W. R., and Ross, J. B. A. (1993) Determination of the tryptophan:tyrosine ratio in proteins, Anal. Biochem. 210, 425-428.
67. Senear, D. F., Mendelson, R. A., Stone, D. B., Luck, L. A., Rusinova, E., and Ross, J. B. A. (2002) Quantitative Analysis of Tryptophan Analogue Incorporation in Recombinant Proteins, Anal. Biochem. 300, 77-86.
68. Siuzdak, G. (1996) Mass Spectrometry for Biotechnology, Academic Press, San Diego, CA.
69. Simpson, R. J., Neuberger, M. R., and Liu, T.-Y. (1976) Complete amino acid analysis of proteins from a single hydrolysate, J. Biol. Chem. 251, 1936-1940.
70. Hasselbacher, C. A., Rusinova, R., Rusinova, E., and Ross, J. B. A. (1995) in Techniques in Protein Chemistry (Crabb, J. W., Ed.) Vol. 6, pp 349-356, Academic Press, New York.
71. Robertson, D. E., Kroon, P. A., and Ho, C. (1977) Nuclear magnetic resonance and fluorescence studies of substrate-induced conformational changes of histidine-binding protein J of Salmonella typhimurium, Biochemistry 16, 1443-1451.
72. Vleugels, N., Gils, A., Bijnens, A.-P., Knockaert, I., and Declerck, P. J. (2000) The importance of helix F in plasminogen activator inhibitor-1, Biochim. Biophys. Acta 1476, 20-26.
73. de Dios, A. C., Pearson, J. G., and Oldfield, E. (1993) Secondary and tertiary structural effects on protein NMR chemical shifts: an ab initio approach, Science 260, 1491-1496.
74. Pearson, J. G., Oldfield, E., Lee, F. S., and Warshel, A. (1993) Chemical shifts in proteins: a shielding trajectory analysis of the fluorine nuclear magnetic resonance spectrum of the Escherichia coli galactose binding protein using a multipole shielding polarizability-local reaction field-molecular dynamics approach, J. Am. Chem. Soc. 115, 6851-6862.
75. Egelund, R., Schousboe, S. L., Sottrup-Jensen, L., Rodenburg, K. W., and Andreasen, P. A. (1997) Type-1 plasminogen-activator inhibitor: conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility, Eur. J. Biochem. 248, 775-785.
76. Fa, M., Bergstrom, F., Hagglof, P., Wilczynska, M., Johansson, L. B.-A., and Ny, T. (2000) The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites, Struct. Fold. Des. 8, 397-405.
77. Fa, M., Bergstrom, F., Karolin, J., Johansson, L. B.-A., and Ny, T. (2000) Conformational studies of plasminogen activator inhibitor type 1 by fluorescence spectroscopy. Analysis of the reactive centre of inhibitory and substrate forms, and of their respective reactive-centre cleaved forms, Eur. J. Biochem. 267, 3729-3734.
78. Wright, H. T., and Scarsdale, J. N. (1995) Structural basis for serpin inhibitor activity, Proteins 22, 210-225.